MedPath

Prospective observational study of Japanese melanoma patients treated with combination therapy using nivolumab and ipilimiumab

Not Applicable
Conditions
Melanoma, advanced
Registration Number
JPRN-UMIN000031736
Lead Sponsor
niversity of Tsukuba
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
100
Inclusion Criteria

Not provided

Exclusion Criteria

Prior treatment with immune checkpoint inhibitors

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Best overall response, overall surviva, adverse events
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath